Schrödinger to Announce Second Quarter 2025 Financial Results on August 6
The live webcast can be accessed in the 'Investors' section of Schrödinger's website and will be archived for approximately 90 days following the event.
About Schrödinger
Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs and is advancing three clinical-stage oncology programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Influenza Pipeline Outlook 2025 – Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight
The Influenza pipeline is experiencing unprecedented growth, driven by 120+ active players, breakthrough therapies, and recent FDA fast-track designations, signaling a transformative decade ahead in Influenza treatment. Influenza Pipeline Summary DelveInsight's Influenza Emerging Drugs report highlights innovative therapies advancing the treatment and prevention of influenza. Key candidates include Moderna's mRNA-1010, a Phase III vaccine encoding HA glycoproteins of WHO-recommended strains; SAB Biotherapeutics' SAB-176, a quadrivalent, broadly neutralizing polyclonal antibody for severe influenza; ENA Respiratory's INNA-051, an immunomodulatory intranasal spray in Phase IIa; Codagenix's CODA-VAX H1N1, a universal live-attenuated flu vaccine in Phase I; and AlloVir's ALVR106, an allogeneic, off-the-shelf VST therapy targeting multiple respiratory viruses. The report further analyzes over 120+ pipeline drugs across various clinical stages, including Phase III, II, I, preclinical, and discovery. It categorizes therapies by route of administration (oral, intravenous, intranasal, inhalation, subcutaneous, etc.), molecule type (antibodies, vaccines, peptides, proteins, immunotherapies, small molecules, stem cells), and product type (mono, combination, or both). Moderna currently leads the late-stage pipeline, showcasing the growing diversity and innovation in influenza treatment strategies. Key Takeaways from the Influenza Pipeline Report Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment. In August 2025, AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination. AstraZeneca launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST®(Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. In July 2025, SK bioscience, a global innovative vaccine and biotech company dedicated to advancing human health from prevention to cure, announced that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. This candidate integrates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu', to improve protective efficacy. SK bioscience previously applied adjuvant technology in its COVID-19 vaccine, 'SKYCovione', and now aims to extend this approach to influenza vaccines as part of its broader platform strategy. In July 2025, GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. In March 2025, Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. In December 2024:- ModernaTX, Inc.- A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age. The purpose the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea). In November 2024:- DiaSorin Molecular LLC- The DiaSorin Molecular LIAISON® NES FLU A/B, RSV & COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. In October 2024:- Pfizer- The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Promising Influenza Therapies such as OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others. Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs Influenza Emerging Drugs · mRNA-1010 (Moderna): A Phase III vaccine targeting WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Yamagata, B/Victoria). Encodes HA glycoproteins to generate broad protection against seasonal influenza. · SAB-176 (SAB Biotherapeutics): A quadrivalent polyclonal antibody therapy developed via DiversitAb™ platform. Designed to neutralize Type A and B influenza viruses, showing broad protection potential. Targeted for severe cases and high-risk groups like elderly and immunocompromised patients. · INNA-051 (ENA Respiratory): An intranasal immunomodulatory spray in Phase IIa trials. Intended for pre- and post-exposure prophylaxis of respiratory viral infections, with potential use across multiple viruses and at-risk populations. · CODA-VAX H1N1 (Codagenix): A live-attenuated universal flu vaccine in Phase I trials. Shows promise for multi-season protection by targeting conserved viral antigens and is being developed into a quadrivalent formulation. · ALVR106 (AlloVir): An allogeneic, off-the-shelf VST therapy in preclinical development. Targets RSV, influenza, PIV, and hMPV, with in vitro data showing strong antiviral activity and potential safety benefits. Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight's detailed report now! @ New Influenza Drugs Key influenza Companies: The following are the leading companies in the influenza market. These companies collectively hold the largest market share and dictate industry trends. Influenza Pipeline Drugs by Route of Administration Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous • Intravenous/ Subcutaneous • NA • Oral • Oral/intranasal/subcutaneous • Parenteral • Subcutaneous Influenza Pipeline Drugs by Molecule Types Influenza Products have been categorized under various Molecule types such as • Antibody • Antisense oligonucleotides • Immunotherapy • Monoclonal antibody • Peptides • Protein • Recombinant protein • Small molecule • Stem Cell • Vaccine Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Influenza Market Drivers and Barriers Scope of the Influenza Pipeline Report Coverage- Global Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Influenza Therapies- OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Table of Content 1. Influenza Report Introduction 2. Influenza Executive Summary 3. Influenza Overview 4. Influenza- Analytical Perspective In-depth Commercial Assessment 5. Influenza Pipeline Therapeutics 6. Influenza Late Stage Products (Phase II/III) 7. Influenza Mid Stage Products (Phase II) 8. Influenza Early Stage Products (Phase I) 9. Influenza Preclinical Stage Products 10. Influenza Therapeutics Assessment 11. Influenza Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Influenza Key Companies 14. Influenza Key Products 15. Influenza Unmet Needs 16 . Influenza Market Drivers and Barriers 17. Influenza Future Perspectives and Conclusion 18. Influenza Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
National Post
27 minutes ago
- National Post
Westaim Reports Q2 2025 Results for the Quarter Ended June 30, 2025
Article content Article content Article content DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES. Article content Implementation of strategic transformation underway following closing of CC Capital transaction Ceres products received regulatory approvals in 43 states plus the District of Columbia Ceres received AM Best Financial Strength Rating of B++ Arena reported $1.2 billion in new AUM and Programmatic Capital in Q2 Article content NEW YORK — The Westaim Corporation (' Westaim ' or the ' Company ') (TSXV: WED) today announces its unaudited interim financial results for the quarter ended June 30, 2025. Westaim recorded a net loss attributable to controlling interests of $0.2 million ($0.01 diluted loss per share) for Q2 2025 compared to a net loss of $17.1 million ($0.80 diluted earnings per share) for Q2 2024. AUM and Programmatic Capital 1 for the Asset Management segment grew by $1.2 billion during Q2 2025, inclusive of the previously announced $0.7 billion mandate entered into on April 1, 2025 and $0.5 billion of incremental mandates during Q2 2025 including $0.3 billion for the Insurance segment. Article content 'With our new corporate structure and our talented executive leadership team in place, Westaim is moving forward to implement our new strategic direction. As expected, Westaim's Q2 2025 was populated by substantial accounting activity, with significant one-time expenses and non-cash gains associated with the implementation of the new business strategy. Our leadership teams at Ceres Life and Arena are positioning their respective businesses to effectively and efficiently execute against Westaim's business strategy.' said Cameron MacDonald, President and Chief Executive Officer of Westaim. 'Notably, Ceres Life has secured necessary licenses, approvals, and received its AM Best Financial Strength Rating of B++. They will officially launch in the first week in September with their distribution partner, Advisors Excel. We were pleased that Arena reported $1.2 billion in new AUM and Programmatic Capital in Q2, commenced managing the Ceres Life investment portfolio, and is realigning its global offices and product offerings to align with our strategic focus. We are confident that the realignment work done to date positions the new Westaim to generate significant long-term value for our stakeholders.' Chinh Chu, Executive Chairman of the Board for Westaim, added, 'We are pleased that our strategic transformation is underway with a new, experienced executive leadership team at the helm. As discussed at our Annual General Meeting on June 12, 2025, all of us at CC Capital are fully committed and aligned to build Westaim into a high-quality business that in time will experience significant profitable growth.' Article content The net loss attributable to controlling interests includes severance expenses of $4.5 million, which are expected to produce estimated annualized run-rate savings of approximately $4.0 million. We have identified an additional $5.0 million of annualized run-rate savings opportunities related to the Asset Management segment that we plan to execute over the course of this fiscal year as we continue to streamline and re-focus the business to align with the Company's core strategic plans, bringing our total identified run-rate savings opportunities to $9.0 million per annum. We will continue to evaluate our business activities for additional operational efficiencies and run-rate savings for the Company over the next quarter as we reposition the Asset Management segment to focus more on scalable opportunities for the Insurance segment, its existing client base, and future third-party clients. Article content At June 30, 2025, Westaim's consolidated shareholders' equity attributable to controlling interests was $686.4 million and the Company had 33,551,508 common shares ('Common Shares') outstanding. Book value per fully diluted share 2 was $20.46 (C$27.88) at June 30, 2025, compared to $22.88 (C$32.90) at December 31, 2024. The net impact of the Strategic Transaction (as defined herein) was a reduction of $1.48 (C$2.08) to book value per fully diluted share. Article content 1 AUM refers to the assets for which Arena Investors provides investment management, advisory or certain other investment-related services. Programmatic Capital includes callable capital to discretionary and non-discretionary separately managed accounts. AUM is generally based on the net asset value of the funds managed by Arena Investors plus any unfunded commitments. Arena Investors' calculation of AUM may differ from the calculations of other asset managers, and as a result, may not be comparable to similar measures presented by other asset managers. Arena Investors' calculations of AUM are not based on any definition set forth in the governing documents of the investment funds and are not calculated pursuant to any regulatory definitions. 2 The Company uses both IFRS and non-generally accepted accounting principles ('non-GAAP') measures to assess performance. Book value per fully diluted share is a non-GAAP measure. Book value per share is computed as adjusted book value divided by the adjusted number of Common Shares. See 'Non-GAAP Financial Measure' and the reconciliation of such measure to the most comparable IFRS figure below. Article content The Strategic Transaction with CC Capital Article content On April 3, 2025, CC Capital Partners, LLC ('CC Capital') and the Company completed its previously announced transaction whereby an affiliate of CC Capital made a significant investment into the Company (the 'Strategic Transaction') as described further in the Company's June 30, 2025 MD&A (as filed on SEDAR+ at Through April 2, 2025, the Company qualified as an investment entity under IFRS and used fair value as the key measure to monitor and evaluate its primary investments. As a result of the Strategic Transaction, the Company transformed from an investment entity into an operating entity and for all reporting periods after April 3, 2025, the financial statements of the Company will be reported on the basis of the Company being an operating entity. As a result of the Strategic Transaction and in accordance with IFRS, the Company now manages its operations and reports its financial results in two operating business segments: Asset Management and Insurance. Other activity for the Company outside of these two operating segments is reporting in the Corporate column of our segment reporting. Article content From Closing Date through June 30, 2025 (US$ in millions) Asset Management Insurance Corporate Eliminations Consolidated Total Revenue 7.7 0.3 3.3 (0.8 ) 10.5 Net results of investments 1.9 1.0 21.7 – 24.6 Total Expenses excluding depreciation, amortization, and income taxes 15.9 12.0 9.2 (0.8 ) 36.4 Earnings before depreciation, amortization, and income taxes ('Adjusted EBITDA') (6.3 ) (10.7 ) 15.8 – (1.2 ) Depreciation and amortization (expense) (0.4 ) – (0.9 ) – (1.2 ) Income taxes recovery (expense) 1.6 3.1 (1.8 ) – 2.9 Net (loss) profit (5.1 ) (7.6 ) 13.2 – 0.5 Net (loss) profit attributable to non-controlling interests 0.7 – – – 0.7 Net (loss) profit attributable to controlling interests (5.8 ) (7.6 ) 13.2 – (0.2 ) Other comprehensive (loss) income – – – – – (Loss) profit and comprehensive (loss) income attributable to controlling interests $ (5.8 ) $ (7.6 ) $ 13.2 $ – $ (0.2 ) NOTE: Schedule subtotals and totals may be impacted by rounding Article content Insurance Article content The Insurance segment, which primarily operates through Ceres Life Insurance Company ('Ceres Life'), had Adjusted EBITDA loss of $10.7 million from the closing of the Strategic Transaction through June 30, 2025, inclusive of $3.6 million of platform build-out related expenses. The Insurance segment is not expected to generate material earnings outside of investment returns on its current cash and portfolio of investments until the annuity business increases in scale. We now have product regulatory approvals in 43 states plus the District of Columbia, enabling a broad launch of our new MYGA product with Advisors Excel which we expect to commence in September 2025. The business believes that the technology and processes underpinning their operations will be able to scale efficiently relative to its peer group, and this operating leverage capability should become more evident as the business scales. Article content Asset Management Article content The Asset Management segment, which primarily operates through Arena Investors Group Holdings, LLC and its subsidiaries and affiliates ('Arena'), had Adjusted EBITDA loss of $6.3 million from the closing of the Strategic Transaction through June 30, 2025, inclusive of the $2.4 million reversal of incentive fees and performance allocations and $1.0 million of non-recurring professional fees related to the Strategic Transaction. Adjusted EBITDA included $10.0 million of management, servicing, and other fee revenues. AUM and Programmatic Capital 1 was $4.6 billion at June 30, 2025, compared to $3.4 billion at December 31, 2024. Fee-paying AUM was $2.7 billion at June 30, 2025 (including $0.3 billion from the Insurance segment), compared to $2.4 billion at December 31, 2024. Article content Corporate and Other Investments Activity Article content While Corporate is not considered a separate operating segment of the Company, the Corporate column of our segment reporting comprises activities of the Company that reside outside of our two operating business segments and includes the investments within the Arena FINCOs, other cash and investments that are held outside of our operating segments, compensation (including share-based compensation) for employees and directors of the company that are not included in our operating segments, and other corporate overhead expenses. Corporate had Adjusted EBITDA gain of $15.8 million, which was driven by a gain on the restructuring of the AIGH investment of $29.0 million and interest income of $3.0 million, offset by losses on Arena FINCO related investments (including related expenses) of $8.1 million, professional fees of $1.3 million, foreign exchange losses largely related to share-based compensation accruals of $0.8 million, non-recurring severance-related expenses of $4.5 million and other operating expenses of $1.5 million. Article content This press release should be read in conjunction with Westaim's unaudited interim consolidated financial statements (the 'Financial Statements') and management's discussion and analysis for the three and six months ended June 30, 2025 and 2024 (the 'MD&A') which were filed on SEDAR+ at These documents and the Company's Q2 2025 Investor Presentation can be found on the Company's website at Article content Non-GAAP Financial Measures Article content Westaim reports its Financial Statements using GAAP and accounting policies consistent with IFRS. Westaim uses both IFRS and non-GAAP measures to assess performance. The Company cautions readers about non-GAAP measures that do not have a standardized meaning under IFRS and are unlikely to be comparable to similar measures used by other companies. Readers are urged to review Section 15 Non-GAAP Measures in the MD&A (available on SEDAR+ at which is incorporated by reference into this news release and discloses historical figures for book value per share in respect to the three and six months ended June 30, 2025 as well as additional disclosures regarding this measure. Additionally, Adjusted EBITDA is a new non-GAAP measure that was introduced as a result of the company's previously announced strategic transaction with CC Capital that closed on April 3, 2023, as described more fully in Section 15 of the MD&A. Article content Long-Term Incentive Plan Amendments Article content Pursuant to the requirements of the TSX Venture Exchange (the ' TSXV '), the Company also today announces that it has amended its long-term equity incentive plan (the ' LTIP ') to permit awards under the LTIP to be granted to persons providing services to Ceres Life. Article content About Westaim Article content Westaim is an integrated insurance and alternative asset management company with two primary operating businesses: Ceres Life and Arena. Article content Ceres Life is a cloud-native, highly scalable, de novo annuity insurance company. Inspired by the belief that technology can reinvent the way insurance providers meet the needs of investors, Ceres Life is building a nimble, highly efficient, and risk-conscious insurance company that provides simple-to-understand and easily accessible annuity products to create better outcomes for policyholders. Ceres Life is led by Deanna Mulligan, former CEO and Chair of Guardian Life Insurance. For more information, see Article content Founded in 2015, Arena is a global institutional asset manager with deep expertise in credit and asset-oriented investments, including the full spectrum of corporate, real estate and structured finance opportunities. With a team of over 180 employees in offices around the world, Arena provides creative solutions for those seeking competitive capital and flexibility to engage in custom transactions. For more information, see Article content Westaim's common shares are listed on the TSXV under the trading symbol 'WED'. Article content For more information, visit our website at or contact: Article content Cautionary Note and Forward-Looking Statements Article content This news release contains certain forward-looking information within the meaning of applicable Canadian securities laws (' forward-looking statements '), including with respect to l. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as 'anticipate', 'achieve', 'could', 'believe', 'plan', 'intend', 'objective', 'continuous', 'ongoing', 'estimate', 'outlook', 'expect', 'project' and similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions 'may' or 'will' occur. These statements are only predictions. Article content Forward-looking statements are based on the opinions and estimates of management of Westaim at the date the statements are made based on information then available to Westaim. Various factors and assumptions are applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements including past practice of the Company. Forward-looking statements are subject to and involve a number of known and unknown, variables, risks and uncertainties, many of which are beyond the control of Westaim, which may cause Westaim's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. Article content No assurance can be given that the expectations reflected in forward-looking statements will prove to be correct. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. Additional information regarding risks and uncertainties relating to the Company's business are contained under the heading ' Risk Factors ' in its annual information form for its fiscal year ended December 31, 2024. Article content Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Article content Article content Article content Article content Article content Article content
Globe and Mail
an hour ago
- Globe and Mail
Lowe's Stock: A Strong Contender in the Home Improvement Sector
Explore the exciting world of Lowe's (NYSE: LOW) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 23, 2025. The video was published on Aug. 21, 2025. Should you invest $1,000 in Lowe's Companies right now? Before you buy stock in Lowe's Companies, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Lowe's Companies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $654,624!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,117!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025
